



## OPEN ACCESS

EDITED AND REVIEWED BY  
Massimiliano Valeriani,  
University of Rome Tor Vergata, Italy

\*CORRESPONDENCE  
Muhammad Sohaib Asghar  
✉ sohaib\_asghar123@yahoo.com

RECEIVED 16 February 2025  
ACCEPTED 25 February 2025  
PUBLISHED 10 April 2025

CITATION  
Raja A, Asim R, Shuja MH, Raja S,  
Muhammad TS, Bajaj S, Ansari AH, Ali H,  
Magsi IA, Faridi MH, Sheikh HAH, Imran MJ,  
Ahmed M and Asghar MS (2025)  
Corrigendum: Atogepant for migraine  
prevention: a meta-analysis of safety and  
efficacy in adults. *Front. Neurol.* 16:1577914.  
doi: 10.3389/fneur.2025.1577914

COPYRIGHT  
© 2025 Raja, Asim, Shuja, Raja, Muhammad,  
Bajaj, Ansari, Ali, Magsi, Faridi, Sheikh, Imran,  
Ahmed and Asghar. This is an open-access  
article distributed under the terms of the  
[Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in  
other forums is permitted, provided the  
original author(s) and the copyright owner(s)  
are credited and that the original publication  
in this journal is cited, in accordance with  
accepted academic practice. No use,  
distribution or reproduction is permitted  
which does not comply with these terms.

# Corrigendum: Atogepant for migraine prevention: a meta-analysis of safety and efficacy in adults

Adarsh Raja<sup>1</sup>, Rabia Asim<sup>1</sup>, Muhammad Hamza Shuja<sup>2</sup>,  
Sandesh Raja<sup>2</sup>, Tazheen Saleh Muhammad<sup>1</sup>, Simran Bajaj<sup>3</sup>,  
Abdul Hadi Ansari<sup>1</sup>, Hamza Ali<sup>1</sup>, Iffat Ambreen Magsi<sup>1</sup>,  
Muhammad Hammad Faridi<sup>1</sup>, Hamza Ali Hasnain Sheikh<sup>1</sup>,  
Muhammad Junaid Imran<sup>1</sup>, Muhammad Ahmed<sup>1</sup> and  
Muhammad Sohaib Asghar<sup>4,5\*</sup>

<sup>1</sup>Department of Internal Medicine, Shaheed Mohtarma Benazir Bhutto Medical College Lyari, Karachi, Pakistan, <sup>2</sup>Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan, <sup>3</sup>Department of Internal Medicine, Shaheed Mohtarma Benazir Bhutto University, Larkana, Pakistan, <sup>4</sup>Department of Internal Medicine, AdventHealth, Sebring, FL, United States, <sup>5</sup>Department of Internal Medicine, Mayo Clinic, Rochester, MN, United States

## KEYWORDS

atogepant, CGRP, migraine, headache, meta-analysis

## A Corrigendum on

### Atogepant for migraine prevention: a meta-analysis of safety and efficacy in adults

by Raja, A., Asim, R., Shuja, M. H., Raja, S., Muhammad, T. S., Bajaj, S., Ansari, A. H., Ali, H., Magsi, I. A., Faridi, M. H., Sheikh, H. A. H., Imran, M. J., Ahmed, M., and Asghar, M. S. (2024) *Front Neurol.* 15:1468961. doi: 10.3389/fneur.2024.1468961

In the published article, there was an error. Two reviewer comments inadvertently appeared in the final published article. Two sentences have been removed from the **Results section**, *Secondary outcomes*. These sentences previously stated:

Regarding change in monthly headache days, I do not see the relevance to do a sensitivity analysis. Also after excluding Ailani et al., the mean value with 95% CI does not appear so different than the previous one.

A sentence has been removed from the **Results section**, *Meta-regression*, *first paragraph*. This sentence previously stated:

The meta-regression is not anticipated in the statistical analysis plan. What is the purpose of such analysis?

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.